The 'Free Consultation' Model
How Prescribing Incentives Are Structured, The Prescriber-Also-Seller Conflict
Evidence grade 3 of 5, Mixed. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Business practice; intersects with telehealth-prescribing rules
Reference only. Not medical advice.
What can go wrong
Bias toward prescribing can lead to treatment of people who do not need it, inadequate screening for contraindications, and difficulty discontinuing (auto-renewing subscriptions with cancellation friction). For testosterone specifically, it can route low-normal men into chronic TRT with its fertility and cardiovascular risks; for ED it can dispense PDE5 inhibitors without adequate cardiac/nitrate screening.
This is something to take to a clinician. The Atlas can tell you what is known about the 'free consultation' model in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Across telehealth platforms and cash-pay clinics, the 'free' or low-cost consultation is a customer-acquisition funnel, not an independent medical evaluation. The structural problem is the prescriber-also-seller conflict: the clinician's employer earns revenue only if the consultation converts to a prescription and an ongoing subscription, so the system is biased toward prescribing rather than reassurance, watchful waiting, or discontinuation. This is the connective tissue linking ED telehealth, low-T clinics, enclomiphene startups, and compounding channels.
If the consult is free, the prescription is the product.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
The funnel monetizes attention: a free/cheap consult lowers the barrier to entry, then revenue comes from the prescribed product and its monthly renewal. Because compensation and platform revenue flow from prescribing and retention, the path of least resistance is to prescribe, the economic gradient runs opposite to conservative care.
The Catch: Evaluation and Sale Are the Same Business
In legitimate medicine, the clinician evaluating you does not profit from selling you a specific product. In the free-consult DTC model, that separation collapses: the same business diagnoses, prescribes, fulfills, and bills the subscription. Asynchronous intake (questionnaire, no live exam) can further weaken screening for contraindications such as nitrate use with PDE5 inhibitors or the need for repeated morning testosterone before diagnosing hypogonadism.
Safety in detail
Prescription sexual-health and hormone interventions require genuine evaluation and monitoring by a qualified physician with no financial stake in the specific prescription. A funnel optimized to convert consults into recurring prescriptions is not a substitute for independent medical judgment.
What people get wrong
Often saidA free online consult is the same as an independent doctor's visit
ActuallyThe consulting clinician's employer profits only if you are prescribed and subscribed; that is a structural bias an independent evaluation does not have.
Often saidAsynchronous questionnaires screen as well as an in-person exam
ActuallyQuestionnaire-only intake can miss contraindications (e.g., nitrate use, the need for repeated low morning testosterone) that a fuller evaluation would catch.
Who profits, and who pushes back
Endocrine Society / urology bodies
Emphasize conservative diagnosis (confirmed low testosterone, genuine symptoms) and careful contraindication screening, standards that prescribe-to-convert funnels can shortcut.
Platforms and clinics, the per-consult-compensated prescribers, fulfillment/compounding pharmacies, and the ad ecosystem that feeds the funnel.
What we do not know
- What conversion-rate and prescribing-rate data would platforms have to disclose to make the conflict transparent?
- Do state telehealth-prescribing rules adequately address asynchronous screening gaps?
At a glance
- 'Free consult' role
- Acquisition funnel, not independent evaluation
- Core conflict
- Prescriber's employer profits from the prescription it writes
- Incidence
- Common across DTC telehealth and cash-pay clinics
- Format risk
- Asynchronous (no live visit) prescribing can under-screen contraindications
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about The 'Free Consultation' Model. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
Sources
No sources recorded for this entry yet. Nothing on this page can be checked against a citation until that changes, so treat it as a summary awaiting its evidence.